abrdn Healthcare Investors (NYSE:HQH) Sets New 12-Month High – Here’s Why

abrdn Healthcare Investors (NYSE:HQH)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $23.15 and last traded at $23.0920, with a volume of 228437 shares trading hands. The stock had previously closed at $23.04.

abrdn Healthcare Investors Price Performance

The business’s 50-day simple moving average is $21.10 and its two-hundred day simple moving average is $19.86.

Institutional Investors Weigh In On abrdn Healthcare Investors

Hedge funds have recently modified their holdings of the company. Bollard Group LLC acquired a new position in abrdn Healthcare Investors in the 1st quarter worth about $25,000. Geneos Wealth Management Inc. boosted its stake in shares of abrdn Healthcare Investors by 9,232.3% during the second quarter. Geneos Wealth Management Inc. now owns 2,893 shares of the financial services provider’s stock valued at $45,000 after purchasing an additional 2,862 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of abrdn Healthcare Investors during the fourth quarter valued at about $48,000. Advisory Services Network LLC bought a new stake in shares of abrdn Healthcare Investors during the third quarter worth about $97,000. Finally, Global Retirement Partners LLC bought a new stake in shares of abrdn Healthcare Investors during the fourth quarter worth about $106,000. Institutional investors and hedge funds own 32.60% of the company’s stock.

About abrdn Healthcare Investors

abrdn Healthcare Investors (NYSE:HQH) is a closed-end management investment company that seeks long-term capital appreciation and current income by investing primarily in equity securities of companies operating in the healthcare sector. The fund’s portfolio generally comprises a diversified mix of domestic and international healthcare issuers, spanning pharmaceuticals, biotechnology, medical devices, healthcare services, and related industries.

The fund employs a fundamental, research-driven approach to select investments, focusing on companies with strong balance sheets, innovative product pipelines and the potential for sustainable revenue growth.